Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-36

There will be two significant Catalysts here that should deliver significant SH Value.

1 The MND Topline Data
2, The FDA granting Orphan Drug Designation

I will then consider the likelihood of a T/O as MT the CEO has disclosed that the current incumbent treatment is under FDA Review , if that MND Treatment has its FDA approval revoked , then the chance of Big Pharma Buying this one very swiftly is High .

@asx11 of all of the ASX Companies I have followed or invested in PAA is the most Undervalued and virtually invisible as the Promotion Historically has been extremely poor , up until November last year the company had not capitalised on any Scientific Progress.. 10 years worth of progress is only now stating to be recognized with any associated value $$$$$